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Heparin’s (HP’s) antiproliferative effect on smooth muscle cells is potentially important in defining new approaches to treat pulmonary
hypertension. The commercially available HP and heparan sulfate (HS) are structurally heterogenous polymers. In order to examine which
sulfonate groups are required for endogenous antiproliferative activity, we prepared the following six chemically modified porcine mucosal
HP and HS, which fell into three groups. One group consisted of fully O-sulfonated-N-acetylated, the second group consisted of de-N-
sulfonated and re-N-acetylated, and the third group consisted of 6-O-desulfonated HP and HS derivatives. These six preparations were
assayed for their antiproliferative potency on bovine pulmonary artery smooth muscle cells. The results of this assay show that (a) over-O-
sulfonation of both HP and HS increases antiproliferative activity, (b) substitution of hexosamine with N-acetyl diminishes antiproliferative
activity in both HP and HS, and (c) 6-O-desulfonation of HP and HS diminishes antiproliferative potency. Surprisingly, the type of uronic
acid residue present at a given level of sulfation is unimportant for antiproliferative potency. In conclusion, only the level of O- and N-sulfo
group substitution correlates well with HP and HS antiproliferative activity.
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1. Introduction the GlcN or at C-2 of the GlcA units) [3]. GlcA is moreHeparin (HP) (1, Fig. 1) and heparan sulfate (HS) (2, Fig.
1) are a family of macromolecules found in virtually all
tissues in a wide variety of species. HP and HS are
chemically similar except for the content of N- and O-sulfo
groups, the content of N-acetyl groups, and ratio of the type
of hexuronic acids [1,2]. These macromolecules are com-
posed of repeating units of alternating glucosamine and
hexuronic acid [either D-glucuronic acid (GlcA) or L-idur-
onic acid (IdoA)] residues with a (1! 4) linkage. Sulfo
substituents occur as N-sulfo [at C-2 of the D-glucosamine
(GlcN) residues] or as O-sulfo groups (at C-6 of the GlcN or
at C-2 of the IdoA units). Irregular regions of these poly-
saccharides can also contain other O-sulfo groups (at C-3 of0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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Sulfo groups in HP appear to play an important role in
the inhibitory effect on smooth muscle cell (SMC) prolif-
eration [5]. Removal of N-sulfo groups from HP reportedly
negates its growth inhibitory effect on SMCs [6]. N-
acetylation after N-desulfonation in HP reportedly does
not restore the SMCs growth inhibitory potency [6]. Earlier
studies [5,7–9] concerning the growth inhibitory effect of
HP on bovine pulmonary artery (BPA) SMCs have shown
that (a) an increase in the charge density of HP affects the
antiproliferative activity; (b) the molecular size of the HP
does not affect the potency of growth inhibition; (c) the
protein core has no antiproliferative activity; (d) the gly-
cosaminoglycan (GAG) chains of HP are responsible for
the antiproliferative activity; (e) 3-O-sulfo group on the
internal GlcN residue is not critical for native HP’s anti-
proliferative activity; (f) N-sulfo groups in HP are not
Fig. 1. Structural formulae of major and variable sequences of repeating disaccharide units of HP and HS preparations. 1, heparin (HP); 2, heparan sulfate (HS);
3, fully O-sulfonated and re-N-acetylated HP; 4, fully O-sulfonated and re-N-acetylated HS; 5, de-N-sulfonated and re-N-acetylated HP; 6, de-N-sulfonated and
re-N-acetylated HS; 7, 6-O-desulfonated HP; 8, 6-O-desulfonated HS.
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sugar residues in HP are replaceable with galactosamine
residues. The objective of the present study is to analyze
further the structural determinants in HP/HS responsible for
the effect on the growth of BPASMCs. We have investi-
gated (a) the requirement for either IdoA or GlcA, (b) the
significance of N-sulfo group of GlcN residues, and (c) the
importance of 6-O-sulfo group of GlcN residues, for
PASMCs proliferation.Table 1
Properties of HP and HS derivatives (1–8)
Compound SO3
/
COO
% 2-O-
SO3

% 6-O-
SO3

% N-SO3
 IdoA/
GlcA
HP 1 2.68 86.2 89.7 90.4 92.3/7.7
3 3.88 100 100 < 0.5 92.3/7.7
5 1.74 86.2 89.7 < 0.5 92.3/7.7
7 1.66 86.2 < 0.5 90.4 92.3/7.7
HS 2 0.25 1.6 6.4 17.5 26.7/73.3
4 3.92 100 100 < 0.5 26.7/73.3
6 0.10 1.6 6.4 < 0.5 26.7/73.3
8 0.19 1.6 < 0.5 17.1 26.7/73.32. Materials and methods
2.1. Materials
Fetal bovine serum and other reagents were obtained
from Sigma Chemical Co. (St. Louis, MO). Porcine mucosal
HP and HS were purchased from Celsus Laboratories. Cell
culture media, RPMI-1640 (Meditech, Washington, DC)
contained streptomycin (Lilly, Indianapolis, IN), penicillin
(Pfizer, New York, NY) and amphotericin B (GIBO, Grand
Island, NY).
2.2. 1H-NMR conditions
1H-NMR spectroscopy was performed using conditions
described previously [10]. Briefly, a HP sample (approxi-
mately 2 mg) was dissolved in 0.5 ml of D2O (99.9%) and
repeatedly freeze-dried to remove exchangeable protons.
The sample was kept in a desiccator over phosphorus
pentoxide in vacuo overnight at room temperature. The
thoroughly dried sample was then dissolved in 0.5 ml of
D2O (99.96%) and passed through 0.45-Am syringe filter
and transferred to a NMR tube (5.0 mm o.d. 25 cm;
Wilmad Glass Co., Buena, NJ). 1D and 2D NMR experi-
ments were performed on a JEOL GSX500A spectrometer
equipped with 5-mm field gradient tunable probe with
standard JEOL software at 303 K for NOE spectra or 333
K for other experiments on 500-Al samples. The HOD signal
was suppressed by presaturation during 3 or 1.5 s for 1D or
2D spectra, respectively. To obtain 2D spectra, 512 experi-
ments resulting to 1024 data points for a spectral width of
2000 Hz were measured, and the time domain data were
multiplied after zero-filling (data matrix size, 11 K) with
a shifted sine-bell window functions for 2D double quantum
filtered (DQF)-COSY, NOESY or TOCSY experiments. An
MLEV-17 mixing sequence of 100 ms was used for 2D
TOCSY and NOESY experiments by using 150, 250 and
500 ms as the mixing times.
2.3. Enzymatic digestion of HP and HS
Complete depolymerization of HP and HS uses a
mixture of HP lyases I, II and III [11]. Briefly, the sample
(V 1 mg in 100 Al of water) was placed in a 500-
Al polypropylene centrifuge tube. Sodium phosphate buffer(10 Al, 500 mM, pH 7.5) was added to the sample, after
which 5–10 mU each of heparin lyase I, II and III are
added. The sample was digested for 8–12 h at 35 jC and
analyzed immediately by the HPLC or stored frozen at
 60 jC until analysis.
2.4. HPLC conditions
The established conditions for the determination of the
sulfated unsaturated disaccharide from HP and HS were as
follows: The HPLC system was assembled with gradient
pumps [Jusco 880-PU, Intelligent HPLC pump (Tokyo,
Japan)], a variable sample injector [VMD-350, Shimamura
Instrument Co., Tokyo, Japan)], a double-plunger pump
(PSU-2.5W, Shimamura Instrument Co.) for delivery of the
post-column reagents, a dry reaction bath (Type DB-3,
Shimamura Instrument Co.), a fluorescence spectrophotom-
eter (Hitachi model F-1050, Hitachi Seisakusho, Tokyo,
Japan) and a chromato-integrator (D-2500, Hitachi Seisa-
kusho). Separation column, Asahipak NH2P-50 (250 4.6
mm i.d.) was from Shodex Co. (Tokyo, Japan). A linear
gradient elution program was started at 100% of eluent A
(0.1 M sodium phosphate buffer, pH 10.0, containing 0.1
M sodium NaCl) to 100% of eluent B (0.1 M phosphate
buffer, pH 10, containing 0.5 M NaCl) for 10 min, and
maintained 100% of eluent B for 10 min, and then returned
to 100% of the initial buffer. Flow rate was constant at 0.5
ml/min sodium hydroxide (0.5 M), and 50 mM guanidine
was added to the eluate of the separation column at a flow
rate of 0.25 ml/min using a double-plunger pump. The
mixture was passed through a polytetrafluoroethylene
(PTFE) reaction coil (10 m 0.5 mm i.d.) set in a dry
reaction bath thermostated at 110 jC and then through a
PTFE cooling coil (2 m 0.25 mm i.d.). The effluent was
monitored by fluorescence with excitation at 320 nm and
emission at 420 nm.
2.5. Fully O-sulfonated re-N-acetylated HP and HS (3,4)
Chemical O-sulfonation to obtain fully sulfated HP and
HS was carried out under mild conditions with adducts of
sulfur trioxide (SO3) in aprotic solvents [12]. Fully O-
sulfated HP and HS were prepared from the tributylamine
(TBA) salt, obtained from 100 mg of each sodium salt by
H.G. Garg et al. / Biochimica et Biophysica Acta 1639 (2003) 225–231228strong cation-exchange chromatography, concentration by
lyophilization. The resulting salt was dissolved in 0.8 ml of
N,N-dimethylformamide (DMF) to which a required excess
(15 mol/equivalent of available hydroxy group in HP or
HS) of pyridine–sulfur trioxide complex had been added.
After 1 h at 40 jC, the reaction was interrupted by additionFig. 2. 1H-NMR analysis of samples of chemically modified HP and HS samples. 3
acetylated HS; 5, de-N-sulfonated and re-N-acetylated HP; 6, de-N-sulfonated anof 1.6 ml of water and the raw product was precipitated
with 3 volumes of cold ethanol saturated with anhydrous
sodium acetate, and then collected by centrifugation. The
resulting fully O-sulfonated HP and HS were dissolved in
water, dialyzed to remove salts and lyophilized. Since
partial loss of N-sulfo groups from GlcNS residues was, fully O-sulfonated and re-N-acetylated HP; 4, fully O-sulfonated and re-N-
d re-N-acetylated HS; 7, 6-O-desulfonated HP; 8, 6-O-desulfonated HS.
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tion was performed according to previously described
methods [13,14].
2.6. De-N-sulfonated re-N-acetylated HP and HS (5,6)
HP or HS sample (5 mg) was dissolved in 10 ml of water
and passed through a Dowex 50WX8 (H+ form, 200–400
mesh) column (0.8 cm i.d. 10 cm) to exchange sodium to
hydrogen ion. The acidic fraction was neutralized with
pyridine and lyophilized. Pyridine complex of GAG was
dissolved in 1.5 ml DMSO containing 5% (v/v) water and
heated at 50 jC for 90 min to remove N-sulfo group
completely. The resulting N-desulfonated HP or HS was
dissolved in 3 ml of water, and 0.5 ml methanol and 90
Al acetic anhydride were added. The pH of the mixture was
adjusted to 6.5 by the addition of 10% sodium hydrogen
carbonate and was kept at 3–4 jC for 2 h. The mixture was
dialyzed against water and lyophilized [14].
2.7. 6-O-desulfonated HP and HS (7,8)
Selective 6-O-desulfonation of intact HP and HS were
achieved according to the method described previously by
Matsuo et al. [15]. Briefly, an aqueous solution of the
sodium salt of HP or HS (10 mg) was passed through a
Dowex 50WX8 (H+ form, 200–400 mesh) column (0.8 cm
i.d. 10 cm) at room temperature, and the eluate was
neutralized with pyridine and lyophilized. The pyridinium
salt of HP or HS was dissolved in 1.0 ml dry pyridine
(Merck, Darmstadt) and 2 ml N,O-bis(trimethylsilyl)aceta-
mide (BTSA) was added. The mixture was kept for 2 h at 70
jC to give a clear solution, and then 1.0 ml water was added
to the mixture to decompose the excess reagent and silyl
ester. The mixture was dialyzed against water and pH was
adjusted to 7.0 with 0.1 M NaOH; the mixture was then
lyophilized to obtain the 6-O-desulfonated HP or HS
sodium salt (7.5 mg).
Characteristics of HP and HS derivatives are summarized
in Table 1. 1H-NMR of HP and HS derivatives (3–8, Fig. 1)
confirmed their structure (Fig. 2).
2.8. Cultured pulmonary artery smooth cells proliferation
assay
Smooth muscle cell proliferation assays were performed
as previously described [8,9]. Briefly, isolated BPASMC
were seeded at 1.25 104 cells/well into six-well tissue
culture plates, grown for 2 days, then growth was arrested
for 48 h by reducing the serum concentration of the medium
from 10% to 0.1%. Media was then changed for experi-
mental samples to contain either standard medium (RPMI-
1640 with 10% FBS), growth arrest media (0.1% FBS) or
standard media containing HP or other GAG derivatives (10
Ag/ml). All media contained streptomycin (10 mg/ml),
penicillin (100 U/ml) and amphotericin B (1.25 Ag/ml).After 4 days, the SMCs present in the cell culture wells
were rinsed with Hank’s balanced salt solution to remove
the remaining cell culture medium and unattached dead
cells. Trypan blue exclusion showed no dead SMC either in
control or in the media treated with GAGs. After detach-
ment of SMCs with trypsin/EDTA, the cell number was
counted by Coulter counter.
The HSs and HPs were each dissolved (1 mg/ml) in
distilled sterile water. This solution (140 Al) was added to
culture medium (13.86 ml), and 2 ml of the resulting media
was added to each well. The GAG preparations (1–6) were
completely soluble as the culture medium was clear (no
turbidity) after addition in the media.
The effective dose of HP previously has been identified
as 1–10 Ag/ml [7]. In the present study, 10 Ag/ml was used
for each of the GAGs.
Growth was measured at a time point corresponding to
the logarithmic growth phase where there is no contact
inhibition among cells [16]. Differences in growth reflected
in the differences in thymidine incorporation was not done
because the secretion of high amounts of endogenous
thymidine in cell culture falsify the assessment of DNA
synthesis with labeled thymidine [17].
The percent inhibition was calculated as: [1 net cell
growth in treated medium/net cell growth in standard
medium]100, where net cell growth = cell growth in stan-
dard or treated medium minus cell growth in growth arrest
media.
2.9. Statistics
Results are presented as meanF S.E. Comparisons
among groups were made with a factorial analysis of
variance (ANOVA), using the stateview software package
(SAS Institute Inc., Cary, NC) for Macintosh computers. If
ANOVA were significant, multiple comparisons were made
using Fisher protected least significant difference (PSLD)
test. In all cases, significance was set as P < 0.0001.3. Results and discussion
Every cell types including vascular endothelial cell
produces HP and HS [18]. All these preparations are
potent inhibitors of SMC proliferation in vitro [19]. How-
ever, due to the limitations of supply from above sources,
we have used in this study commercial porcine mucosal
HP and HS. HP differs from HS primarily in its higher
content of both O- and N-sulfo groups, and its higher
content of iduronic acid, which is mainly sulfonated at its
2-position. These structural features lead to a slightly (but
not significantly) higher level of activity at a concentration
of 10 Ag, on the percent inhibition of proliferation of
bovine pulmonary artery SMCs (Fig. 3). Full O-sulfonation
and re-N-acetylation of the amine groups afford HP deriv-
ative 3 and HS derivative 4. When added individually to
H.G. Garg et al. / Biochimica et Biophysica Acta 1639 (2003) 225–231230cultured BPASMCs, both 3 and 4 show significantly
increased inhibition of cell growth in comparison to
unmodified HP 1 and HS 2. Interestingly, the activity of
HP derivatives 3 and HS derivative 4 were not signifi-
cantly different from each other (HP 3, 60.21F 4.0 and
HS 4, 58.76F 4.5% inhibition). These results suggest that
while oversulfation enhances antiproliferative activity, dif-
ferences in the GlcA/IdoA ratio in repeating disaccharide
units have no effect on the antiprolifertive potency. Pre-
liminary data suggests that inhibitory properties of modi-
fied HP/HS are reversible.
The importance of the N-acetyl/N-sulfo ratio in GlcN
residues on antiproliferative potency is not well understood.
Castellot et al. [20,21] have reported that N-sulfo groups on
GlcN residues in HP can be replaced by N-acetyl groups
without significant loss of antiproliferative activity. On the
other hand, Tiozzo et al. [6] reported that N-reacetylation
following N-desulfonation does not restore HP antiprolifer-
ative activity. However, a recent report has shown that HP
antiproliferative activity on bovine pulmonary artery
smooth muscle cells requires both N-acetylation and N-
sulfonation on GlcN [22]. To further clarify the above
discrepancy, HP derivative 5 and HS derivative 6 were
assayed for their antiproliferative activity on BPASMCs.
While both derivatives showed reduced activity when
compared to HP 1 and HS 2, derivative 5 (31.85F 6.0%
inhibition) and derivative 6 (30.43F 5.9% inhibition)
showed no significant difference in their antiproliferative
potency. These results suggest that the N-acetyl content
GlcN residues in either HP or HS are not critical for
antiproliferative potency but rather that removal of N-sulfo
groups in either HP or HS reduces overall negative charge
and results in reduced antiproliferative activity.
In an attempt to determine the contribution of 6-O-sulfo
groups of GlcN residues to the growth inhibition ofFig. 3. Inhibition of PASMC proliferation by modified HP, HS, including starting
cell grown in media containing 10% FBS without HP or HS as negative control (
10% FBS plus porcine lung HP (1), column 3; 10% FBS plus porcine mucosa HS
HP (3), column 5; 10% FBS plus fully O-sulfonated-re-N-acetylated HS (4), colum
FBS plus de-N-sulfonated-re-N-acetylated HS (6), column 8; 10% FBS plus 6-O
column 10. ‘‘a’’ represents a significant inhibition in cell growth compared to HPBPASMCs, 6-O-desulfonated HP derivative 7 and HS
derivative 8 were prepared. Both HP derivative 7 and HS
derivative 8 show reduced antiproliferative activity com-
pared to unmodified HP 1 and HS 2. HP derivative 7
(35.15F 5.4% inhibition) was not significantly different
from HS derivative 8 (33.75F 5.4% inhibition) in affecting
growth inhibition of BPASMCs. These results show that 6-
O-sulfo groups of GlcN residues are not essential for
antiproliferative activity but again merely contribute to the
overall level of sulfation. The antiproliferative effect of HP/
HS might involve interaction of these GAGs with growth
factors, growth factor receptors, chemokines and other
proteins. There are many potential targets, and the structural
requirements for GAG-binding are unclear for most of
these. Furthermore, commercial HP and HS are heteroge-
nous polymers composed of repeating uronic acid-GlcN
disaccharide units that have undergone a variety of chemical
modifications during maturation [16]. These modifications
include C-5 epimerization of D-GlcUA to L-Ido, O-sulfona-
tion of GlcN residues at C-6 and C-3 and N-sulfonation.
These structural variations are important in determining the
biological activity of a particular preparation. In a previous
study, we have shown that 3-O-sulfonation is not critical in
native HP [8]. The data obtained in our laboratory suggests
that either or/and N- or C-6-sulfonate (s) in native HP may
be important for antiproliferative activity.
In conclusion, although the structural requirements for
antiproliferative activity are still not fully understood, we
have demonstrated that (a) oversulfonation of both HP and
HS increases antiproliferative activity, (b) the ratio of D-
glucuronic acid/iduronic acid residues in the repeating
disaccharide has no effect on antiproliferative potency, (c)
N-sulfo and 6-O-sulfo present in the GlcN residues of HP
and HS are and their loss reduces the overall sulfation level
reducing antiproliferative potency.HP and HS. Percent inhibition of bovine pulmonary artery smooth muscle
), column 1; 0.1% FBS without HP or HS as positive control (+), column 2;
(2), column 4; containing 10% FBS plus fully O-sulfonated-re-N-acetylated
n 6; 10% FBS plus de-N-sulfonated-re-N-acetylated HP (5), column 7; 10%
-desulfonated HP (7), column 9; 10% FBS plus 6-O-desulfonated HS (8),
; ‘‘b’’ represents a significant inhibition in cell growth compared to HS.
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